Johnson & Johnson (NYSE: JNJ) announced new data from its Phase 3 Vivacity-MG3 study, showing that IMAAVY (nipocalimab-aahu) maintains disease control in adults with generalized myasthenia gravis through 120 weeks of follow-up. The comprehensive study tracked 153 antibody-positive patients, including individuals with anti-AChR and anti-MuSK antibodies.

Significant Reductions in Symptom Burden

During the 96-week open-label extension phase, IMAAVY drove notable clinical improvements. Patients achieved mean reductions of 6.47 points on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale and 5.97 points on the Quantitative Myasthenia Gravis (QMG) scale. These critical metrics assess how symptoms impact daily routines and overall muscle strength.

The treatment also delivered distinct milestones in symptom management:

• Half of the trial participants achieved minimal symptom expression.
• Nearly one-third of the patient population maintained this minimal symptom status for at least eight weeks.
• IMAAVY enabled 57% of patients to reach low corticosteroid doses of 10 mg or less per day.
• The therapy reduced total immunoglobulin G levels by more than 64%.

Superior Efficacy Versus Placebo

A post-hoc analysis from the initial 24-week double-blind period further highlighted the drug’s impact. Patients taking IMAAVY alongside standard of care proved four times more likely to achieve sustained minimal symptom expression than those receiving a placebo. As a direct result, individuals who maintained this high level of symptom control reported substantial improvements in their overall quality of life.

Constantine Farmakidis, Associate Professor of Neurology at the University of Kansas Medical Center, emphasized the clinical value of the data. “These long-term results, now extending to beyond two years, provide further evidence that disease control can be sustained,” he stated.

Expanding Clinical Milestones

Johnson & Johnson showcased these findings among seven abstracts at the American Academy of Neurology 2026 Meeting in Chicago. Building on this momentum, the company is actively enrolling participants for its EPIC study. This new trial will compare IMAAVY directly against efgartigimod in adults with generalized myasthenia gravis who have no prior exposure to an FcRn blocker.

Currently, IMAAVY holds regulatory approval for treating generalized myasthenia gravis in adults and pediatric patients 12 years and older who test positive for AChR or MuSK antibodies.

For more investor relations information on Johnson & Johnson please visit www.investor.jnj.com.

The post Johnson & Johnson Reports Sustained Efficacy of IMAAVY for Generalized Myasthenia Gravis appeared first on PRISM MarketView.